Home > Boards > US Listed > Biotechs >

Enanta Pharmaceuticals (ENTA)

ENTA RSS Feed
Add ENTA Price Alert      Hide Sticky   Hide Intro
Moderator: DewDiligence
Search This Board: 
Last Post: 3/26/2020 5:58:25 PM - Followers: 76 - Board type: Free - Posts Today: 0
ENTA
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
ENTA News: Statement of Changes in Beneficial Ownership (4) 02/18/2020 06:40:08 AM
ENTA News: Statement of Changes in Beneficial Ownership (4) 02/18/2020 06:27:38 AM
ENTA News: Statement of Changes in Beneficial Ownership (4) 02/18/2020 06:24:20 AM
ENTA News: Statement of Changes in Beneficial Ownership (4) 02/18/2020 06:23:23 AM
ENTA News: Statement of Changes in Beneficial Ownership (4) 02/18/2020 06:22:55 AM
PostSubject
#1858  Sticky Note ENTA's COVID-19 update: #msg-154596451. DewDiligence 03/26/20 04:42:49 PM
#1860   Addendum—ENTA’s COVID-19 PR is silent about expected Mavyret DewDiligence 03/26/20 05:58:25 PM
#1859   ENTA new corporate slide set: DewDiligence 03/26/20 05:38:14 PM
#1858   ENTA's COVID-19 update: #msg-154596451. DewDiligence 03/26/20 04:42:49 PM
#1856   ENTA new slide set—includes info on COVID-19 discovery program: DewDiligence 03/18/20 12:21:38 PM
#1855   Baird upgrades 'defensive' Enanta, sees 'real COVID-19 potential' biocqr 03/17/20 09:07:06 AM
#1854   I don't consider today's PR promotional as much DewDiligence 03/13/20 03:16:34 PM
#1853   ENTA isn’t getting a bounce from this announcement—and DaveAu 03/13/20 03:12:04 PM
#1852   ENTA’s PR on COVID-19 effort: DewDiligence 03/13/20 11:41:57 AM
#1850   ENTA’s CEO is a 5.8% shareholder—1.19M shares by DewDiligence 03/04/20 05:11:04 PM
#1849   USPSTF recommends HCV screening for all US adults DewDiligence 03/02/20 04:53:55 PM
#1848   ENTA FY1Q20 CC transcript: DewDiligence 02/10/20 05:47:30 PM
#1847   EDP-514 (for HBV) has a higher probability of DewDiligence 02/09/20 06:07:37 PM
#1846   How would you rank the prob of success semi_infinite 02/09/20 02:17:57 PM
#1845   Thanks for posting that excerpt. EDP-297 sounds highly DewDiligence 02/09/20 12:07:28 PM
#1844   https://seekingalpha.com/article/4322273-enanta-pharmaceuticals-inc-enta-ce DaveAu 02/09/20 11:38:35 AM
#1843   ABBV’s 2020 HCV guidance=$2.5B—essentially the same run rate DewDiligence 02/07/20 09:45:40 AM
#1842   ENTA new corporate slide set: DewDiligence 02/06/20 04:34:49 PM
#1840   ENTA FY1Q20* results: DewDiligence 02/06/20 04:22:05 PM
#1839   Looks like Spring Bank Pharma tanked on their DewDiligence 01/29/20 12:42:05 PM
#1837   Looks like Spring Bank Pharma tanked on their JK2016 01/29/20 12:25:59 PM
#1836   I concur with the report that the phase-1 DewDiligence 01/21/20 12:31:27 PM
#1835   Good to see their mention of EDP-297; I DewDiligence 01/21/20 12:29:27 PM
#1834   BUY rating issued by ROTH Capital Partners... some JK2016 01/21/20 12:09:15 PM
#1833   The FY2019 annual-meeting proxy (DEF14A) has been filed: DewDiligence 01/17/20 05:22:37 PM
#1832   ENTA new corporate slide set: DewDiligence 01/13/20 06:03:16 PM
#1831   ENTA—Re: hMPV DewDiligence 01/13/20 05:45:18 PM
#1830   ENTA 2020 clinical goals: DewDiligence 01/09/20 10:48:15 AM
#1829   One more HBV competitor bites the dust: #msg-152982734. DewDiligence 12/26/19 10:50:39 AM
#1828   ENTA's enterprise value at the current share price DewDiligence 12/25/19 08:26:01 PM
#1827   ENTA’s pro forma cash @9/30/19=$444.2M—an increase of $13.4M DewDiligence 12/25/19 08:23:20 PM
#1826   ENTA’s fully-diluted* share count @9/30/19=22.7M—unchanged since 6/30/19 DewDiligence 12/25/19 08:22:42 PM
#1825   ENTA FY4Q19 CC transcript: DewDiligence 11/27/19 04:23:19 PM
#1824   ENTA’s insiders are bullish: #msg-152478615. DewDiligence 11/25/19 05:22:00 PM
#1823   New corporate slide set: DewDiligence 11/21/19 05:32:37 PM
#1822   ENTA’s follow-on FXR agonist is called EDP-297. Phase-1 DewDiligence 11/21/19 04:24:24 PM
#1821   ENTA FY4Q19 results: DewDiligence 11/21/19 04:09:40 PM
#1820   Yet another: #msg-151617214. DewDiligence 10/09/19 05:37:59 PM
#1819   EDP-938 ancillary phase-2a data presented at IDWeek: DewDiligence 10/03/19 08:27:53 AM
#1818   Another bullish insider transaction: #msg-151441695. DewDiligence 09/30/19 05:04:54 PM
#1817   Musings on ENTA’s buyout vig: #msg-151399889. DewDiligence 09/27/19 02:51:31 PM
#1816   Deja vu? willyw 09/27/19 01:21:23 PM
#1815   FDA shortens approved Mavyret regimen for treatment-naïve cirrhotics DewDiligence 09/27/19 09:12:28 AM
#1814   FDA shortens approved Mavyret regimen for treatment-naïve cirrhotics DewDiligence 09/27/19 02:03:28 AM
#1813   Many thanks! I always appreciate your informed and willyw 09/26/19 10:13:43 PM
#1812   This isn’t a yes/no binary matter—it’s a question DewDiligence 09/26/19 08:51:55 PM
#1811   "It might be a mistake to interpret Luly’s willyw 09/26/19 07:16:21 PM
#1810   I'm certainly not as up to speed as willyw 09/26/19 05:47:55 PM
#1809   You make some good points. However, I’m not DewDiligence 09/26/19 05:07:00 PM
#1808   Oh, I'm in agreement that Viekira wasn't a willyw 09/26/19 04:31:18 PM
#1807   I harken back to Viekira. What if ENTA DewDiligence 09/26/19 03:08:38 PM
PostSubject